Chemosensitization and mitigation of Adriamycin-induced cardiotoxicity using combinational polymeric micelles for co-delivery of quercetin/resveratrol and resveratrol/curcumin in ovarian cancer

Octavia, 2012, Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies, J Mol Cell Cardiol, 52, 1213, 10.1016/j.yjmcc.2012.03.006 Mitry, 2016, Doxorubicin induced heart failure: Phenotype and molecular mechanisms, IJC Heart Vasc, 10, 17, 10.1016/j.ijcha.2015.11.004 Chatterjee, 2010, Doxorubicin Cardiomyopathy, Cardiology, 115, 155, 10.1159/000265166 Barrett-Lee, 2009, Expert opinion on the use of anthracyclines in patients with advanced breast cancer at cardiac risk, Ann Oncol, 20, 816, 10.1093/annonc/mdn728 Cardinale, 2004, Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy, Circulation, 109, 2749, 10.1161/01.CIR.0000130926.51766.CC Saidi, 2011, Management of chemotherapy induced cardiomyopathy, Curr Cardiol Rev, 7, 245, 10.2174/157340311799960681 Kumar, 2012, Doxorubicin-induced cardiomyopathy 17 years after chemotherapy, Tex Heart Inst J, 39, 424 Smith, 2016, Is it equivalent? Evaluation of the clinical activity of single agent Lipodox® compared to single agent Doxil® in ovarian cancer treatment, J Oncol Pharm Pract, 22, 599, 10.1177/1078155215594415 Yamaguchi, 2015, Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis, Eur J Cancer, 51, 2314, 10.1016/j.ejca.2015.07.031 Cohn, 2015, The cost implications of the use of pegylated liposomal doxorubicin when choosing an anthracycline for the treatment of platinum-resistant ovarian cancer: A low-value intervention?, Gynecol Oncol Rep, 13, 47, 10.1016/j.gore.2015.06.009 Spallarossa, 2016, A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology J Cardiovasc Med (Hagerstown), 17, S84, 10.2459/JCM.0000000000000381 Cvetković, 2005, Dexrazoxane: a review of its use for cardioprotection during anthracycline chemotherapy, Drugs, 65, 1005, 10.2165/00003495-200565070-00008 Vittorio, 2017, Polyphenols delivery by polymeric materials: challenges in cancer treatment, Drug Delivery, 24, 162, 10.1080/10717544.2016.1236846 Cote, 2015, Combinatorial resveratrol and quercetin polymeric micelles mitigate doxorubicin induced cardiotoxicity in vitro and in vivo, J Control Release, 213, 128, 10.1016/j.jconrel.2015.06.040 Carlson, 2014, Polymeric Micellar Co-delivery of Resveratrol and Curcumin to Mitigate In Vitro Doxorubicin-Induced Cardiotoxicity, J Pharm Sci, 103, 2315, 10.1002/jps.24042 Andreadou, 2007, Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress, J Mol Cell Cardiol, 42, 549, 10.1016/j.yjmcc.2006.11.016 Elias, 1977, Heart/body weight ratios for aging high and low blood pressure mice, Exp Aging Res, 3, 231, 10.1080/03610737708257106 Hangartner, 1985, The assessment of cardiac hypertrophy at autopsy, Histopathology, 9, 1295, 10.1111/j.1365-2559.1985.tb02811.x Tacar, 2013, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems: Doxorubicin cell and molecular biological activity, J Pharm Pharmacol, 65, 157, 10.1111/j.2042-7158.2012.01567.x Deres, 2005, Prevention of doxorubicin-induced acute cardiotoxicity by an experimental antioxidant compound, J Cardiovasc Pharmacol, 45, 36, 10.1097/00005344-200501000-00007 Langer, 2014, Dexrazoxane for the treatment of chemotherapy-related side effects, Cancer Manag Res, 6, 357, 10.2147/CMAR.S47238 Payne, 2017, Prevention of Chemotherapy Induced Cardiomyopathy, Curr Heart Fail Rep, 14, 398, 10.1007/s11897-017-0353-9 Deffie AM, Batra JK and Goldenberg GJ. Direct correlation between DNA topoisomerase II activity and cytotoxicity in adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res 1989; 49: 58-62. 1989/01/01. Groarke, 2015, Anthracycline cardiotoxicity: a new paradigm for an old classic, Circulation, 131, 1946, 10.1161/CIRCULATIONAHA.115.016704 Kemp, 2004, Biochemical markers of myocardial injury, Br J Anaesth, 93, 63, 10.1093/bja/aeh148 Walker, 2006, Serum Chemical Biomarkers of Cardiac Injury for Nonclinical Safety Testing, Toxicol Pathol, 34, 94, 10.1080/01926230500519816